Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71:209–49.
Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol. 2021;18:282–301.
Article CAS PubMed Google Scholar
Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238–44.
Article CAS PubMed Google Scholar
Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4:365–80.
PubMed PubMed Central Google Scholar
Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501–11.
Article CAS PubMed PubMed Central Google Scholar
Li JKM, Wang LL, Wong CYP, Chiu PKF, Teoh JYC, Kwok HSW, et al. A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2021;24:1063–72.
Article CAS PubMed Google Scholar
Markowski MC, Sfanos KS. The interplay of microbiota and hormone regulation in men with prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:935–6.
Article PubMed PubMed Central Google Scholar
Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, et al. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 2018;21:539–48.
Article CAS PubMed PubMed Central Google Scholar
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7.
Article CAS PubMed Google Scholar
Terrisse S, Goubet AG, Ueda K, Thomas AM, Quiniou V, Thelemaque C, et al. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J Immunother Cancer. 2022;10:e004191.
Article PubMed PubMed Central Google Scholar
Pernigoni N, Zagato E, Calcinotto A, Troiani M, Mestre RP, Calì B, et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science. 2021;374:216–24.
Article CAS PubMed Google Scholar
Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60.
Article PubMed PubMed Central Google Scholar
Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
Article PubMed PubMed Central Google Scholar
Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv. 2020:2020.08.10.244293. https://doi.org/10.1101/2020.08.10.244293.
Anderson MJ. Permutational multivariate analysis of variance. Department of Statistics, Univerisity of Auckland. 2005;26:32–46.
Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106:581–8.
Article CAS PubMed Google Scholar
Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study. Prostate Cancer Prostatic Dis. 2014;17:338–42.
Article CAS PubMed PubMed Central Google Scholar
Kelly TN, Bazzano LA, Ajami NJ, He H, Zhao J, Petrosino JF, et al. Gut microbiome associates with lifetime cardiovascular disease risk profile among bogalusa heart study participants. Circ Res. 2016;119:956–64.
Article CAS PubMed PubMed Central Google Scholar
Kure A, Tsukimi T, Ishii C, Aw W, Obana N, Nakato G, et al. Gut environment changes due to androgen deprivation therapy in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2023;26:323–30.
Zhong W, Wu K, Long Z, Zhou X, Zhong C, Wang S, et al. Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome. 2022;10:94.
Article CAS PubMed PubMed Central Google Scholar
Fujita K, Matsushita M, Banno E, De Velasco MA, Hatano K, Nonomura N, et al. Gut microbiome and prostate cancer. Int J Urol. 2022;29:793–8.
Article CAS PubMed Google Scholar
Martins CDA, Rocha GDG, Gattass CR, Takiya CM. Pomolic acid exhibits anticancer potential against a docetaxel‑resistant PC3 prostate cell line. Oncol Rep. 2019;42:328–38.
Matsushita M, Fujita K, Hayashi T, Kayama H, Motooka D, Hase H, et al. Gut microbiota–derived short-chain fatty acids promote prostate cancer growth via IGF1 signaling. Cancer Res. 2021;81:4014–26.
Article CAS PubMed Google Scholar
Ma Y, Zhu L, Ma Z, Gao Z, Wei Y, Shen Y, et al. Distinguishing feature of gut microbiota in Tibetan highland coronary artery disease patients and its link with diet. Sci Rep. 2021;11:18486.
Article CAS PubMed PubMed Central Google Scholar
Zapatero A, Guerrero A, Maldonado X, Alvarez A, Segundo CGS, Rodríguez MAC, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:320–7.
Article CAS PubMed Google Scholar
Jain S, Samal AG, Das B, Pradhan B, Sahu N, Mohapatra D, et al. Escherichia coli, a common constituent of benign prostate hyperplasia-associated microbiota induces inflammation and DNA damage in prostate epithelial cells. Prostate. 2020;80:1341–52.
Article CAS PubMed Google Scholar
Tsai KY, Wu DC, Wu WJ, Wang JW, Juan YS, Li CC, et al. Exploring the association between gut and urine microbiota and prostatic disease including benign prostatic hyperplasia and prostate cancer using 16S rRNA sequencing. Biomedicines. 2022;10:2676.
Article CAS PubMed PubMed Central Google Scholar
Li L-Y, Han J, Wu L, Fang C, Li W-G, Gu J-M, et al. Alterations of gut microbiota diversity, composition and metabonomics in testosterone-induced benign prostatic hyperplasia rats. Military Med Res. 2022;9:12.
Liu X, Tang H, Zhou Q, Zeng Y, Lu B, Chen D, et al. Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events. Front Immunol. 2023;14:1109281.
Article CAS PubMed PubMed Central Google Scholar
Cai S, Yang Y, Kong Y, Guo Q, Xu Y, Xing P, et al. Gut Bacteria Erysipelatoclostridium and Its Related Metabolite Ptilosteroid A Could Predict Radiation-Induced Intestinal Injury. Front Public Health. 2022;10:862598.
Freier TA, Beitz DC, Li L, Hartman PA. Characterization of eubacterium coprostanoligenes sp. nov., a cholesterol-reducing anaerobe†. Int J Syst Evol Microbiol. 1994;44:137–42.
Miller WL. Androgen biosynthesis from cholesterol to DHEA. Mol Cell Endocrinol. 2002;198:7–14.
Article CAS PubMed Google Scholar
Mohiuddin JJ, Baker BR, Chen RC. Radiotherapy for high-risk prostate cancer. Nat Rev Urol. 2015;12:145–54.
Mjaess G, Karam A, Roumeguère T, Diamand R, Aoun F, McVary K, et al. Urinary microbiota and prostatic diseases: the key for the lock? A systematic review. Prostate Cancer Prostatic Dis. 2022;26:451–60.
Lombardo R, Tema G, Cornu JN, Fusco F, McVary K, Tubaro A, et al. The urothelium, the urinary microbioma and men LUTS: a systematic review. Minerva Urol Nefrol. 2020;72:712–22.
Kwa WT, Sundarajoo S, Toh KY, Lee J. Application of emerging technologies for gut microbiome research. Singapore Med J. 2023;64:45–52.
Article PubMed PubMed Central Google Scholar
Liu C, Cui Y, Li X, Yao M. microeco: an R package for data mining in microbial community ecology. FEMS Microbiol Ecol. 2021;97:fiaa255.
Comments (0)